REG - Marshall Wace LLP Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Co Ltd
RNS Number : 4139MMarshall Wace LLP07 January 2019FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Marshall Wace LLP (on behalf of itself and its affiliates)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
04 Jan 2019
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES
If YES, specify which:
Shire plc
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary shares (ISIN: JP3463000004) - interest and short positions partially held via ADSs (ISIN: US8740602052)
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
1,756,662
0.22%
834,638
0.11%
(2) Cash-settled derivatives:
1,239,566
0.16%
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:
1,756,662
0.22%
2,074,204
0.26%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
Ordinary Shares
Sale
888
JPY 3652.4502
Ordinary Shares
Sale
60
JPY 3645.7333
Ordinary Shares
Sale
10,500
JPY 3672.5667
Ordinary Shares
Purchase
34,700
JPY 3675.9597
Ordinary Shares
Sale
20
JPY 3674
Ordinary Shares
Sale
128
JPY 3683.125
Ordinary Shares
Sale
290
JPY 3672.3914
Ordinary Shares
Sale
502
JPY 3686.1434
Ordinary Shares
Sale
1,544
JPY 3675.5941
Ordinary Shares
Sale
15,868
JPY 3626.4532
ADS
Sale
1,435
USD 17.262923
ADS
Sale
1,761
USD 17.262923
ADS
Sale
9,104
USD 17.262923
ADS
Sale
82
USD 17.257143
ADS
Sale
100
USD 17.257143
ADS
Sale
518
USD 17.257143
ADS
Sale
13
USD 17.4
ADS
Sale
11
USD 17.4
ADS
Sale
70
USD 17.4
ADS
Sale
378
USD 17.31948
ADS
Sale
462
USD 17.31948
ADS
Sale
2,361
USD 17.321041
ADS
Sale
352
USD 17.289753
ADS
Sale
164
USD 17.375714
ADS
Sale
1,484
USD 17.316301
ADS
Sale
13,283
USD 17.308048
ADS
Sale
1,795
USD 17.331998
ADS
Sale
2,707
USD 17.301574
ADS
Sale
1,625
USD 17.376622
ADS
Sale
1,236
USD 17.392021
ADS
Sale
8,339
USD 17.377115
ADS
Sale
927
USD 17.3939
ADS
Sale
1,217
USD 17.378607
ADS
Sale
5,911
USD 17.391484
ADS
Sale
16,329
USD 17.3759
ADS
Sale
2,475
USD 17.385
ADS
Sale
3,164
USD 17.3764
ADS
Purchase
2,886
USD 17.712003
ADS
Purchase
200
USD 17.665
ADS
Purchase
18,200
USD 17.706648
ADS
Purchase
24,000
USD 17.716292
ADS
Purchase
17,400
USD 17.713017
ADS
Purchase
19,906
USD 17.707005
ADS
Purchase
37,215
USD 17.7069
ADS
Sale
59,549
USD 17.79
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary Shares
CFD
Increasing a short position
72
JPY 3680
Ordinary Shares
CFD
Increasing a short position
2,512
JPY 3652.935591
Ordinary Shares
CFD
Increasing a short position
25,632
JPY 3627.904209
Ordinary Shares
CFD
Increasing a short position
140
JPY 3649.685714
Ordinary Shares
CFD
Increasing a short position
24,200
JPY 3677.431818
Ordinary Shares
CFD
Increasing a short position
610
JPY 3664.928689
Ordinary Shares
CFD
Increasing a short position
80
JPY 3674
Ordinary Shares
CFD
Increasing a short position
2,456
JPY 3669.801591
Ordinary Shares
CFD
Increasing a short position
298
JPY 3681.731544
ADS
CFD
Reducing a short position
59,549
USD 17.79
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
07 Jan 2019
Contact name:
Matthew Rooney
Telephone number:
020 7316 2253
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETBSGDBUSGBGCR
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement